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Opportunities, Challenges, and StrategiesYan Liu, MD, PHD, Xuming Dai, MD, PHDR esearch during cardiology fellowship isimportant for fellows-in-training, advancingknowledge on cardiovascular diseases and
improving quality of patient care. However, the
challenges are real and have been well outlined
(1,2). Individualized and systematic strategies to
overcome these challenges, including an innovative
American College of Cardiology Research Network,
have been intensively discussed in recent Fellows-
in-Training (FIT) & Early Career (EC) pages (2,3).
An important question is how a young investigator
with limited research experience could work around
these challenges and produce high-quality data that
affect patient care directly. However, fellows have
the advantage of being at the front line in cardio-
vascular care by being in direct contact with a large
number of patients. This exposes the clinically
important knowledge gaps and reveals the unmet
need of clinical research. Funding is an important
aspect of research, but there are alternate sources
often looking for clinical collaborations actively (4).
By taking advantage of the above, we propose that
fellow-initiated clinical trials (FiCTs) are not only
feasible, but also a fundamental form of research in
modern cardiology FIT and EC development.
FiCTs refer to clinical trials that arise from the
initiative of a fellow or an EC cardiologist who serves
as the principle investigator (PI), while a senior fac-
ulty member either supervises or serves as co-PI.
FiCTs often focus on a speciﬁc but novel clinical
question, with a design feasible to complete within
the duration of the fellow’s training. Unlike large
industry-sponsored trials, which are usually designed
to test a new medication or technology (5,6), FiCTsFrom the Division of Cardiology, Department of Medicine, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina.usually focus on highly hypothesis-driven, single-
center, smaller studies aiming to identify new ways of
using existing, less expensive treatments or technol-
ogies with well-known safety proﬁles; a novel use of a
diagnostic test; or a new strategy to improve the ef-
ﬁcacy, cost-effectiveness, and quality of patient care.
In this paper, we propose a stepwise strategy of
planning and conducting an FiCT, including how to
take on the challenges and maximize our opportu-
nities, with a goal to provide a blueprint that a young
investigator can use to start his/her ﬁrst trial.
The 10 steps of FiCTs are as follows:
1. Ask a clinically important and novel question.
Identifying a “gap” in the available evidence or an
unmet clinical need is the ﬁrst step leading to
important and novel research. The idea has to be
unique. A careful and detailed search of the
published data will help to verify that the gap
truly exists and highlight some of the challenges
faced by other investigators working around a
relatively similar concept. This will lead to a
better understanding of the subject and lead to
the design of a better protocol and, ultimately, a
more reﬁned study.
2. Find a mentor. Establishing a mutually beneﬁcial
mentor–mentee relationship is vital for FiCTs.
Discussing the idea with your advisers or experts
in the ﬁeld before proceeding to next steps is
essential for a polished hypothesis and will save
you a lot of time going forward. A good mentor is
one of the key determining factors of successful
and productive research during fellowship.
3. Find collaborators, locally or through networking.
Equipped with a common interest, the collabora-
tors can be a start-up company, a PhD researcher,
a core laboratory facility, a colleague, or a non-
proﬁt organization. Once you have a research
question in mind, the next step will be to conduct
J A C C V O L . 6 6 , N O . 3 , 2 0 1 5 Liu and Dai
J U L Y 2 1 , 2 0 1 5 : 3 2 4 – 7 Fellows-in-Training & Early Career Page
325a search through the published data or networks
to ﬁnd a collaborator of common interest, which
will dramatically enhance your chance to get
funded and later execute on the trial. For
example, a start-up company that is developing
a novel clinical assay would be eager to collabo-
rate on a trial testing the clinical utility of the
assay.
4. Getting funded. When it comes down to getting
funded, FiCTs should focus on state or local
sources, instead of competing for federal funding
with pure PhD researchers or large trial in-
stitutions. There is a national consortium of >60
medical research institutions in >30 states with
translational or clinical research funding of vari-
able sizes to support smaller, local clinical studies
(7). The industry funding sources, especially start-
up companies, are also especially suitable when
you are collaborating with them already. The
translational institutions often have designated
funding to bring local clinical researchers and
start-up companies together—a great opportunity
for FITs.
5. Institutional review board and clinical trial ofﬁce
process—appropriate expectation and planning.
With collaborators and funding in hand, it seems
that the rest of the process would be easier. The
reality is often quite the opposite, as now the
process of working with the institutional review
board (IRB)/clinical trial ofﬁce starts. The IRB and
research account set-up processes are time-
consuming, and sometimes tedious and frus-
trating. Planning ahead and having appropriate
expectations will make your experience with
them more efﬁcient and satisfactory. A reasonable
strategy is to work around your rotation schedule,
get the proposal done during an easy rotation,
and wait for the IRB while you are kept busy
anyway with calls and nights.
6. Putting together a good team is essential. The
quality of your team determines the fate of your
trial. The clinical trial coordinator is responsible
for daily patient recruitment and follow-up. Hir-
ing someone who ﬁts the budget, is eager to learn,
and is motivated is easier said than done, but
college graduates who are interested in pursuing
a career in medicine or clinical research are
not too difﬁcult to ﬁnd. Some institutions have
coordinators who can help. Regardless, a multi-
disciplinary team with a physician, coordinator,
statistician, nurses, residents, and students—as
well as insight and oversight from senior physi-
cians and researchers—is the basis for a successful
trial.7. Supporting environment and resources—improvi-
sation and improvement. Starting a clinical trial
as a fellow or an EC does not mean recruiting
patients alone, but instead means acting as a
physician leader who works with supporting staff.
The supporting environment for FiCTs varies
among different institutes and is overall not yet
optimized; even some prestigious clinical re-
search institutions may not have a good FiCT
supporting mechanism. Some institutions have
designated coordinators and trial managers
working with fellows with a goal to help with trial
planning, IRB, funding management, and even
hiring and training of new project-speciﬁc co-
ordinators, which is a good mechanism to poten-
tially model after. Improvisation in different
supporting environments is needed from an FIT
standpoint to keep your FiCTs ongoing, but
improvement is warranted from an institutional
aspect to encourage FiCTs.
8. Balancing between clinical duty and research—for
now and for the future as a cardiologist. During the
whole process of FiCTs, clinical training and
patient care are the more important counterparts.
Therefore, balancing between research and
patient care is a constant routine for your present
and future career. Three important points to
remember are: 1) be a planner: set your timetable
early, weeks or even months earlier so you are
always prepared; 2) be a learner: talk to and learn
from experienced senior cardiologists and ﬁeld
experts so that you will save time “staring at the
map,” as they will often point you in the right
direction; and 3) be a leader: pick the right team
members, motivate and organize your team,
and trust them to do their job and help them
if needed. Good leadership improves team efﬁ-
ciency and saves time for everybody.
9. Aim for meaningful publications—design, execution,
and analysis. A meaningful publication is the most
effective way for FiCTs to have an effect on patient
care. In addition to the novel and important
question asked, there are 3 indispensable steps
to publication: the appropriate design makes
the study powerful; the good execution makes
the study of high quality; and the thoughtful
data analysis makes the study of signiﬁcance.
Following the stepwise strategies outlined in the
previous text may not guarantee but at least will
maximize the chance for FiCTs to have meaningful
publications in the end.
10. Timing. Fellowship training is limited to 3 to 4
years in most programs. FiCTs require early
initiation to recruit adequate patients, complete
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fore, it is never too early to start planning for your
trial during fellowship.
In summary, FiCTs should be considered as a
fundamental form of research training in modern car-
diology fellowship. As we discuss the strategies of
performing FiCTs as fellows or EC cardiologists, we
also call for improvement of the supporting environ-
ment for FiCTs from an institutional standpoint.
Institutional effort on this aspect will not only
stimulate vigorous fellow-initiated clinical research,but also improve health care efﬁcacy and cost-
effectiveness as a whole.
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2015.RESPONSE: Are We Committed to Training
Fellows in Clinical Investigation?
Christopher M. O’Connor, MD
Fairfax, Virginia
E-mail: christopher.oconnor@inova.orgThe paper by Drs. Liu and Dai describes the opportunities
and value of conducting fellow-initiated clinical trials.
It sheds light on the important challenges that we face
as cardiovascular leaders in training the next generation
of cardiovascular clinical investigators. I commend the
authors for comprehensively highlighting the activities that
must occur to conduct a successful fellow-initiated clinical
trial, but the question may overlook the true problem we
will face in the future. Namely, how can we train the next
generation of cardiovascular clinical investigatorswhen there
is a predicted shortage of clinical cardiologists and research
training funds over the next 20 years?
The resources for academic training programs continue
to decrease and adversely affect the opportunity to
appropriately train cardiologists in clinical research. In
contrast, the future is bright for improving cardiovascular
human health over the next several decades, because
every day new molecules, devices, and biological thera-
peutics are discovered and enter the arena of human
investigation. Yet, if we do not have a national commit-
ment from the U.S. cardiovascular community to trainclinical investigators, none of these opportunities will
emerge. For example, LCZ696, a drug that the cardiovas-
cular community was committed to test against
angiotensin-converting enzyme inhibitors, was found to
improve clinical outcomes in heart failure patients. This
positive result was due in part to the contributions of
many highly experienced and skilled cardiovascular clin-
ical investigators (1).
Today, as I look at training programs across the United
States, I am concerned about the reduction in protected
time for fellows to take part in clinical investigations. As
1 of the architects of the clinical investigator track in the
Duke Heart Failure Fellowship, I felt it was imperative for
future clinical investigators to complete a minimum of
1 year and preferably 2 years of protected time for clinical
research training with qualiﬁed mentorship, didactic
coursework, investigative initiatives around retrospective
database analyses, prospective design of clinical registries
or pilot clinical trials, the development of peer-review
grants, participation in a multicenter study team, and
conducting site-based research.
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327The undertaking of a clinical trial by fellows is
complex, and it also requires the leadership and
endorsement of cardiovascular program directors, divi-
sion chiefs, and health system administrators to be
possible. These trials require signiﬁcant resources
because of the requirements for a data safety moni-
toring board, institutional review board reviews, adju-
dication committee, monitoring, and audits, so that our
patients can expect the highest level of protection
against harm and the greatest likelihood of success.
Cardiovascular leaders need to convince their health
systems that this is a valued investment. Currently,
many health systems rely on fellows, instead of hospi-
talists, for high-level care at a modest cost. These sav-
ings should be returned to the training programs forfellow research. Many of these private clinical trials
afford opportunities to improve the value of care in the
health systems by reducing length of stay, reducing
readmissions, and improving survival. More importantly,
in addition, these pilot studies can be the basis for peer-
reviewed grants from the National Institute of Health
or other institutions, resulting in millions of dollars back
to the institution (2–5).
Thus, I applaud the authors for their continued interest
to develop as clinical investigators, and yet, they should
not believe that conducting a clinical trial would result in
them becoming certiﬁed clinical investigators. A more
comprehensive approach to their education is necessary.
They should be the advocates for this, and as leaders, we
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